CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival

American Journal of Pathology

Volumn 161, Issue 4, 2002, Pages 1215-1221

  Kristiansen, Glen ^a   Denkert, Carsten ^a   Schlüns, Karsten ^a   Dahl, Edgar ^b   Pilarsky, Christian ^b   Hauptmann, Steffen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b metaGen Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CELL SURFACE PROTEIN; CYTOPLASM PROTEIN; GLYCOSYLATED PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; MOLECULAR MARKER;

ADENOMA; ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; EPITHELIUM; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UNDIFFERENTIATED CARCINOMA;

EID: 0036792566     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64398-2     Document Type: Article

References (39)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47
2. Pisani P, Parkin DM, Bray F, Ferley J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999, 83:18-29
3. Trope C: Prognostic factors in ovarian cancer. Cancer Treat Res 1998, 95:287-352
4. Masciullo V, Ferrandina G, Pucci B, Fanfani F, Lovergine S, Palazzo J, Zannoni G, Mancuso S, Scambia G, Giordano A: P27/Kip1 Expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis Clin Cancer Res 2000, 6:4816-4822
5. Gotlieb WH, Goldberg I, Weisz B, Davidson B, Novikov I, Kopolovic J, Ben-Baruch G: Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer, Gynecol Oncol 2001, 82:99-104
6. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Araki T, Sugisaki Y: Prognostic significance of vascular endothelial growth factor expression in human ovarian cancer. Br J Cancer 2000, 83:196-203
7. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001, 7:2396-2404
8. Hata K, Fujiwaki R, Nakayama K, Miyazaki K: Expression of the endostatin gene in epithelial ovarian cancer. Clin Cancer Res. 2001, 7:2405-2409
9. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Pincinno R, Rigault de la Longrais IA, Howarth DJC, Diamandis EP: Prognostic value of human kallikrein 10 expression in epithelial ovarian cancer. Clin Cancer Res 2001, 7:2372-2379
10. Schmitt AO, Specht T, Beckmann G, Dahl E, Pilarsky CP, Hinzmann B, Rosenthal A: Exhaustive mining of EST libraries for genes differentially expressed in normal and tumor tissues. Nucleic Acids Res 1999, 27:4251-4260
11. Pirucello SJ, LeBien TW: The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986, 136:3779-3784
12. Fischer GF, Majdic O, Gadd S, Knapp W: Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990, 144:638-641
13. Lavabre-Bertrand T, Duperray C, Brunet C, Poncelet P, Exbrayat C, Bourquard P, Lavabre-Bertrand C, Brochier J, Navarro M, Janossy G: Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias. Leukemia 1994, 8:402-408
14. Akashi T, Shirasawa T, Hirokawa K: Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines. Virchows Arch 1994, 425:399-406
15. Poncet C, Frances V, Gristina R, Scheiner C, Pellissier JF, Figarella-Branger D: CD24, a glycosylphosphatidylinositol-anchored molecules is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors. Acta Neuropathol (Berl) 1996, 91:400-408
16. Cram DS, McIntosh A, Oxbrow L, Johnston AM, DeAizpurua HJ: Differential mRNA display analysis of two related but functionally distinct rat insulinoma (RIN) cell lines: identification of CD24 and its expression in the developing pancreas. Differentiation 1999, 64:237246
17. Shirasawa T, Akashi T, Sakamoto K, Takahashi H, Maruyama N, Hirokawa K: Gene expression of CD24 core peptide molecule in developing brain and developing non-neural tissues. Dev Dyn 1993, 198:1-13
18. Figarella-Branger D, Moreau H, Pellissier JF, Bianco N, Rougon G: CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle. Acta Neuropathol (Berl) 1993, 86:275-284
19. Redondo P, Garcia-Foncillas J, Okroujnov I, de Felipe I, Quintanilla E: CD24 expression on human keratinocytes Exp Dermatol 1998, 7:175-178
20. Droz D, Zachar D, Charbit L, Gogusev J, Chrétien Y, Iris L: Expression of the human nephron differentiation molecules in renal cell carcinoma. Am J Pathol 1990, 137:895-905
21. Pirrucello SJ, Lang MS: Differential expression of CD24-related epitopes in mycosis fungoides/Sezary syndrome: a potential marker for circulating Sezary cells. Blood 1990, 76:2343-2347
22. Raife TJ, Lager DJ, Kemp JD, Dick FR: Expression of CD24 (BA-1) predicts monocytic lineage in acute myeloid leukemia. Am J Clin Pathol 1994, 101:296-299
23. Jackson D, Waibel R, Weber E, Bell J, Stahel RA: CD24, a signaltransducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 1992, 52:5264-5270
24. Karran L, Jones M, Morley G, van Noorden S, Smith P, Lampert I, Griffin BE: Expression of a B-cell marker, CD24, on nasopharyngeal carcinoma cells. Int J Cancer 1995, 60:562-566
25. Huang LR, Hsu HC: Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995, 55:4717-4721
26. Senner V, Sturm A, Baur I, Schrell UH, Distel L, Paulus W: CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol 1999, 58:795-802
27. Gromova I, Gromov P, Celis JE: Identification of true differentially expressed mRNAs in a pair of human bladder transitional cell carcinomas using an improved differential display procedure. Electrophoresis 1999, 20:241-248
28. Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P, Sthoeger ZM: CD24 is a marker for human breast carcinoma. Cancer Lett 1999, 143:87-94
29. Yang GP, Ross DT, Kuang WW, Brown PO, Weigel RJ: Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Res 1999, 27:1517-1523
30. Liu W, Vadgama JV: Identification and characterization of amino acid starvation-induced CD24 gene in MCF-7 in human breast cancer cells. Int J Oncol 2000, 16:1049-1054
31. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001, 98:1176-1181
32. Sammar M, Aigner S, Hubbe M, Schirrmacher V, Schachner M, Vestweber D, Altevogt P: Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int Immunol 1994, 6:1027-1036
33. Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, Butcher EC, Vestweber D, Altevogt P: Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol 1995, 7:1557-1565
34. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P: CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997, 89:3385-3395
35. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K: CD24 mediates rolling of breast carcinoma cells on P-selectin EMBO J 1998, 12:1241-1251
36. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P: The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000, 60:6714-6722
37. Fischer A, Blanche S, Le Bidois J, Bordigoni P, Garnier JL, Niaudet P, Morinet F, Le Deist F, Fischer AM, Griscelli C: Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991, 324:1451-1456
38. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P, Garnier JL, Le Bidois J, Le Deist F, Blanche S, Fischer A: Anti-B-cell monoclonal antibody treatment of severe post-transplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998, 92:3137-3147
39. Garnier JL, Stevenson G, Blanc-Brunat N, Touraine JL, Milpied N, Leblond V, Blay JY: Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies. Recent Results Cancer Res 2002, 159:113-122